carbostyril has been researched along with Tuberculosis, Pulmonary in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (52.63) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Chi, Z; Pan, X; Tang, W; Yin, Y; Zhao, M | 1 |
| Jung, KS; Kim, CJ; Kim, S; Kim, YS; Lee, YC; Lim, SY; Oh, YM; Park, JW; Park, MJ; Shim, JJ; Yoo, CG; Yoo, KH; Yoon, HK | 1 |
| Balfour-Lynn, IM | 1 |
| Hanna, D; Romero, K; Schito, M | 1 |
| Bai, Y; Hu, Z; Li, J; Lu, J; Luo, R; Tang, Z; Wang, H; Wu, J; Xian, Q; Yue, J; Zhang, X | 1 |
| de Souza, MV; Facchinetti, V; Gomes, CR; Vasconcelos, TR | 1 |
| Feng, B; Jiang, P; Li, HM; Wang, GY; Wang, W; Zhang, F | 1 |
| Bitting, C; Gruppo, V; Johnson, CM; Lenaerts, AJ; Marietta, KS; Orme, IM; Woolhiser, L | 1 |
| Heilmann, HD; Sirgel, FA; Venter, A | 1 |
| Cynamon, MH; Klemens, SP; Rogge, MC; Sharpe, CA | 1 |
| Grosset, J; Ji, B; Lalande, V; Paccaly-Moulin, A; Truffot-Pernot, C | 1 |
| Klinberg, NM; Mar'iandyshev, AO; Moroz, MI; Shonbina, AI | 1 |
| Padeĭskaia, EN | 1 |
| Koriakin, VA; Kunichan, AD; Lazareva, IaV; Sokolova, GB | 1 |
| Grishin, VK; Polunina, TE | 1 |
| Martynova, LP; Mishin, VIu; Vasil'eva, IA | 1 |
| Elistratova, NA; Kunichan, AD; Mozhokina, GN; Perel'man, MI; Sokolova, GB | 1 |
| Kamisaka, K; Kawahara, S; Kibata, M; Konishi, H; Matsuyama, T; Mishima, Y; Shiomi, K; Tada, A; Takeuchi, M; Yoshimoto, S | 1 |
| Eirei, J; Kawahara, S | 1 |
3 review(s) available for carbostyril and Tuberculosis, Pulmonary
| Article | Year |
|---|---|
Clinical papers of the year 2018 - Cystic fibrosis.
Topics: Administration, Inhalation; Aminophenols; Aminopyridines; Anti-Bacterial Agents; Azithromycin; Benzodioxoles; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Chloride Channel Agonists; Cough; Cross Infection; Cystic Fibrosis; Disease Progression; Drug Combinations; Drug Therapy, Combination; Humans; Indoles; Lung Transplantation; Microbiological Techniques; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Nebulizers and Vaporizers; Proton Pump Inhibitors; Pseudomonas aeruginosa; Pseudomonas Infections; Pyrazoles; Pyridines; Pyrrolidines; Quinolones; Randomized Controlled Trials as Topic; Saline Solution, Hypertonic; Specimen Handling; Sputum; Treatment Outcome; Tuberculosis, Pulmonary | 2020 |
Perspectives on the development of novel potentially active quinolones against tuberculosis and cancer.
Topics: Animals; Antineoplastic Agents; Antitubercular Agents; Cell Line, Tumor; Cell Survival; Drug Design; Drug Discovery; Humans; Mice; Microbial Viability; Mycobacterium tuberculosis; Neoplasms; Quinolones; Structure-Activity Relationship; Tuberculosis, Pulmonary | 2012 |
[Difluoroquinolone lomefloxacin (Maxaquin): its role among fluoroquinolones, possibilities and prospectives].
Topics: Anti-Infective Agents; Antitubercular Agents; Fluoroquinolones; Humans; Legionellosis; Meningitis, Bacterial; Quinolones; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 1998 |
5 trial(s) available for carbostyril and Tuberculosis, Pulmonary
| Article | Year |
|---|---|
Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Female; Forced Expiratory Volume; Health Status; Humans; Indans; Lung; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Recovery of Function; Republic of Korea; Severity of Illness Index; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary | 2017 |
[Lomefloxacin in complex treatment of acute progressive form of pulmonary tuberculosis].
Topics: Acute Disease; Adolescent; Adult; Animals; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Mice; Middle Aged; Pyrazinamide; Quinolones; Streptomycin; Treatment Outcome; Tuberculosis, Pulmonary | 1998 |
[Lomefloxacin in phthisiatric practice].
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Anti-Infective Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Fluoroquinolones; Glutamate Dehydrogenase; Humans; Male; Middle Aged; Quinolones; Transaminases; Treatment Outcome; Tuberculosis, Pulmonary | 1998 |
[Maxaquin in the combined treatment of tuberculosis].
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Culture Techniques; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fluoroquinolones; Humans; Lung; Mice; Mycobacterium tuberculosis; Quinolones; Time Factors; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2000 |
[Evaluation of new antitubercular agents--new quinolone agents].
Topics: Antitubercular Agents; Drug Resistance, Microbial; Humans; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Tuberculosis, Pulmonary | 1992 |
11 other study(ies) available for carbostyril and Tuberculosis, Pulmonary
| Article | Year |
|---|---|
Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Cost-Benefit Analysis; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Pneumonia; Quinolones; Randomized Controlled Trials as Topic; Tuberculosis, Pulmonary | 2022 |
Advancing tuberculosis drug regimen development through innovative quantitative translational pharmacology methods and approaches.
Topics: Antitubercular Agents; Cardiovascular System; Clinical Trials, Phase III as Topic; Computer Simulation; Drug Discovery; Humans; Models, Biological; Quinolones; Research Design; Risk Factors; Translational Research, Biomedical; Tuberculosis, Pulmonary | 2017 |
In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Cell Line, Tumor; Colony Count, Microbial; Drug Evaluation, Preclinical; Female; Haplorhini; Humans; Hydrazines; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Quinolones; Spleen; Survival Analysis; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2010 |
[Study on mutations of gyrA gene of tuberculosis quinolone-tolerant isolates in coal workers' pneumoconiosis].
Topics: Aged; Aged, 80 and over; Antibiotics, Antitubercular; Coal Mining; DNA Gyrase; Drug Resistance, Bacterial; Humans; Male; Middle Aged; Mutation; Mycobacterium tuberculosis; Pneumoconiosis; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Quinolones; Tuberculosis, Pulmonary | 2006 |
Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.
Topics: Animals; Antitubercular Agents; Biological Availability; Interferon-gamma; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyridones; Quinolones; Treatment Outcome; Tuberculosis, Pulmonary | 2008 |
Comparative in-vitro activity of Bay y 3118, a new quinolone, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Mycobacterium tuberculosis; Quinolones; Sputum; Tuberculosis, Pulmonary | 1995 |
Activity of levofloxacin in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Culture Media; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Levofloxacin; Lung; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Spleen; Stereoisomerism; Tuberculosis, Pulmonary | 1994 |
Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice.
Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Female; Fluoroquinolones; Lung; Mice; Mycobacterium tuberculosis; Quinolones; Spleen; Tuberculosis, Pulmonary | 1993 |
[Use of maxaquin in the treatment of progressive pulmonary tuberculosis occurring with standard chemotherapy regimens].
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Disease Progression; Drug Resistance, Microbial; Fluoroquinolones; Follow-Up Studies; Humans; Middle Aged; Mycobacterium tuberculosis; Quinolones; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 1997 |
[Efficiency of lomefloxacine in combined treatment of patients with multiresistant pulmonary tuberculosis complicated with nonspecific bronchopulmonary infection].
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Fluoroquinolones; Humans; Isoniazid; Middle Aged; Quinolones; Respiratory Tract Infections; Rifampin; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 1999 |
[A case of pulmonary atypical mycobacteriosis complicated with aplastic anemia, treated with surgical resection and postoperative sparfloxacin].
Topics: Anemia, Aplastic; Anti-Infective Agents; Antitubercular Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluoroquinolones; Humans; Male; Middle Aged; Mycobacterium Infections, Nontuberculous; Pneumonectomy; Quinolones; Tuberculosis, Pulmonary | 1992 |